About the Study

Acute Lymphoblastic Leukemia (ALL): A study of chemotherapy and Tyrosine Kinase Inhibitors with Blinatumomab in Patients with Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia

This study is for: -Children age 1-22 -With newly-diagnosed Ph+ or ABL-class Ph-like B-ALL The purpose of this study is to test the combination of dasatinib or inatinib to chemotherapy treatment with blinatumomab for children, adolescents, and young adults with Philadelphia chromosome positive or ALB-class Philadelphia chromosome-like B-cell ALL.

Interested in learning more?

Full Study Name: AALL2131: An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors with Blinatumomab in Patients with Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia